By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for Iniparib
Email this page to a colleague
What is the development status for investigational drug Iniparib?
Iniparib is an investigational drug.
There have been 20 clinical trials for Iniparib.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Sanofi, SOLTI Breast Cancer Research Group, and UNC Lineberger Comprehensive Cancer Center.
Summary for Iniparib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,354 |
| WIPO Patent Applications | 1,058 |
| Japanese Patent Applications | 452 |
| Clinical Trial Progress | Phase 3 (2009-07-01) |
| Vendors | 107 |
Recent Clinical Trials for Iniparib
| Title | Sponsor | Phase |
|---|---|---|
| Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | Sanofi | Phase 3 |
| A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | Sanofi | Phase 1 |
| Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients | SOLTI Breast Cancer Research Group | Phase 2 |
Clinical Trial Summary for Iniparib
Top disease conditions for Iniparib
Top clinical trial sponsors for Iniparib
US Patents for Iniparib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
